ArticleCureus2025
Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) is a prevalent mental health condition with significant cognitive impairments, affecting millions worldwide. Cognitive dysfunction in MDD, encompassing attention, memory, executive function, and processing speed deficits, increases the disease burden and impacts treatment outcomes. Vortioxetine, a multimodal antidepressant, and escitalopram, a selective serotonin reuptake inhibitor, have both been utilized for MDD treatment, yet their comparative effects on cognitive function remain under-explored.
aimThis study aimed to compare the effects of vortioxetine and escitalopram on cognitive function in patients with MDD. METHODOLOGY: This prospective, randomized follow-up study (October 2023-2024) assessed 150 MDD patients meeting the following criteria: Montreal Cognitive Assessment Scale (MoCA) score ≤ 26 and Brief Cognitive Rating Scale (BCRS) score ≥ 1. Patients were randomly assigned to escitalopram (10 mg, n = 78) or vortioxetine (10 mg, n = 72), with 50 per group analyzed at the final evaluation. Cognitive function was assessed using MoCA and BCRS at baseline, week two, and week four.
resultsBoth vortioxetine and escitalopram improved cognitive function over four weeks. While the reduction in BCRS scores showed no statistically significant difference between the groups, MoCA scores indicated a slight advantage for escitalopram by the fourth week (p = 0.05). These findings suggest that both drugs effectively improve cognitive function, with escitalopram demonstrating a slight cognitive advantage over the study period.
conclusionBoth vortioxetine and escitalopram improve cognitive symptoms in MDD, with escitalopram showing a modest cognitive advantage by the 4th week. These results support the efficacy of both medications for cognitive symptoms in MDD, with escitalopram potentially offering a slight edge in cognitive enhancement. Further long-term studies are warranted to confirm these findings and investigate the underlying neurobiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.